On January 17, 2017, Generex Biotechnology Corporation entered into the acquisition agreement with the equity owners of Hema Diagnostic Systems, LLC. Closing under the acquisition agreement occurred January 18. At the closing of the acquisition, the company's board of directors was reconstituted by the appointment of Joseph Mosacato, serving as Chairman of the Board, Andrew Greene, Esq., Andrew Ro, Jason Terrell, MD, Gary H. Lyman, MD, Craig Eagle, MD and Jacob Dagan, Ph.D; and the resignation of Mark Fletcher as a director . At the Effective Time, executive management team was also reconstituted by the resignations of Mark Fletcher as President and Chief Executive Officer (Mr. Fletcher remains Executive Vice President, Secretary and General Counsel) and David Brusegard, as Secretary and Chief Operating Officer; and appointment of Joseph Moscato as Chief Executive Officer, President, Chairman of the Board, Andrew Greene, Esq. as Chief Operating Officer, Director, Andrew Ro as Chief Investment Officer, Senior VP of Investments, Director, Mark Corrao as Chief Financial Officer, Treasurer, Jason Terrell, MD as Chief Scientific Officer, Chief Medical Officer, Mark Fletcher, Esq. as Executive Vice President & General Counsel, Secretary, Richard Purcell as Senior VP of Research & Drug Development, Lawrence Salvo as Senior VP of Diagnostic, CEO and President of HDS, Director, Gary H. Lyman, MD as Director, Craig Eagle, MD as Director, Jacob Dagan, Ph.D as Executive Vice President Business Development, James M. Anderson, Jr. as Director and Brian T. McGee as Director. Joseph Moscato. Mr. Moscato serves as the Chief Executive Officer, President and Chairman of the Board. Since 2009, Mr. Moscato has been working as an exclusive consultant to Generex Biotechnology Corp. Mr. Greene has over 20 years of experience in all aspects of corporate management, board of director development, operations, marketing, financing and legal. He has owned and operated his own management and corporate consulting and legal advisory firm focused on early stage companies regarding their business plan development, roll out of operations and management execution as well as implementing cost savings initiatives. Mr. Greene has conducted due diligence for all phases of corporate execution; has developed expertise in operational plans and strategies including growth, marketing, technology, and expansion. Mr. Ro was a Partner with an active Investment Fund where he was involved in originating, structuring, negotiating and closing financing transactions providing growth capital, acquisition financing, recapitalization, restructuring and general working capital to late-stage venture, distressed and middle market companies across all industries and sectors. From 2012 to present Mr. Corraohas been a Managing Director and CFO of The Mariner Group LLC. Dr. Terrell previously served as a Corporate Medical Director for Any Lab Test Now. Purcell headed the Life Sciences Consulting Group for Kline and Company, where he conducted market, technology and business analysis for the commercial development of pharmaceutical and biotechnology products for therapeutic and diagnostic applications. Mr. Fletcher has served as President and Chief Executive Officer of Generex Biotechnology Corp, the predecessor company, since March 2011. Mr. Fletcher has served as a member of the Board of Directors at the comapny's annual meeting of stockholders. He has served as Executive Vice President and General Counsel and continues in his role as General Counsel. Prior to joining, Mr. Fletcher was engaged in the private practice of law as a partner at Goodman and Carr LLP. Mr. Salvo has over 20 years of experience in the design and development of rapid medical diagnostic tests for infectious diseases and over 30 years has successfully been directly involved in the management of international distribution and sales including high technology areas in electro-optics and other technical design applications. During that time, Mr. Salvo has developed and maintained substantial and long-term relationships within the People's Republic of China as well as throughout South and Central America and into the African Continent. Dr. Lyman is Professor of Medicine and Director of Comparative Effectiveness and Outcomes Research - Oncology
at Duke University and the Duke Cancer Institute. Dr. Eagle serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at
Pfizer Inc. In 2003, Dr. Eagle led the worldwide development of Celecoxib in oncology to oversee the global research program. He was responsible for the global research plans and teams for Irinotecan and Dalteparin. Dr. Dagan is a senior executive, with more than 25 years of proven success, in: healthcare management,
corporate and product development, in the US. Combining extensive experience, in operations, marketing, sales and hospital management, with strong bio medical scientific skills. In 2005 founded with partners ProMed Capital, LLC, an investment organization investing in Israeli medical device startups. Since 2006 invest in
eight companies, and six more are in the pipe line. In each company, hands on involvement as active manager, board member or chairman of the board. Continues to own and operate Medical Service Options (MSO-Israel). Member on the Board of Governors of the Technion-Israel Institute of Technology. In 2016 started a
corporation for contract development and manufacturing of medical and health related lasers. Currently acts as CEO of a multi-specialty surgical corporation in the City of New York. Dr. Anderson has previously served as Chairman of the Corporate Governance and Nominating Committee and a member of the Generex Compensation Committee, and has served on the Generex Scientific Advisory Board since October 2010. He is currently CEO and President of Symcopeia. Mr. McGee has previously served as Chairman of the Generex Audit Committee and a member of the Generex Compensation Committee and the Generex Corporate Governance and Nominating Committee. Mr. McGee has been a partner of Zeifmans LLP since 1995.